Re-purposed medicines are showing effectiveness against TB, but aren't registered for that purpose, which hinders their use in treating TB patients. High prices are another significant barrier to accessing promising new and re-purposed drugs. In this fact sheet, MSF looks at accessibility of five key drugs: bedaquiline, delamanid, imipenem/cilastatin, clofazimine and linezolid.
Msf Issuebrief Drtb Readysetslowdown
pdf — 3.72 MB